MPPE1 and cancer: To evaluate the feasibility of cDC1 reprogramming in situ as a cancer immunotherapeutic modality, we first assessed whether the PIB transcription factors were sufficient to drive in vivo reprogramming of tumor cells to immunogenic cDC1-like cells within the TME without relying on artificial antigens or exogenous stimulation and characterized induced immune mechanisms.